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Background. Patients undergoing emergency gastrointestinal surgery for intra-abdominal infection are at risk of
invasive candidiasis (IC) and candidates for preemptive antifungal therapy.
Methods. This exploratory, randomized, double-blind, placebo-controlled trial assessed a preemptive antifungal
approach with micafungin (100 mg/d) in intensive care unit patients requiring surgery for intra-abdominal infection.
Coprimary efﬁcacy variables were the incidence of IC and the time from baseline to ﬁrst IC in the full analysis set;
an independent data review board conﬁrmed IC. An exploratory biomarker analysis was performed using logistic
regression.
Results. The full analysis set comprised 124 placebo- and 117 micafungin-treated patients. The incidence of IC
was 8.9% for placebo and 11.1% for micafungin (difference, 2.24%; [95% conﬁdence interval, −5.52 to 10.20]). There
was no difference between the arms in median time to IC. The estimated odds ratio showed that patients with a
positive (1,3)-β-D-glucan (ßDG) result were 3.66 (95% conﬁdence interval, 1.01–13.29) times more likely to have
conﬁrmed IC than those with a negative result.
Conclusions. This study was unable to provide evidence that preemptive administration of an echinocandin was
effective in preventing IC in high-risk surgical intensive care unit patients with intra-abdominal infections. This may
have been because the drug was administered too late to prevent IC coupled with an overall low number of IC events.
It does provide some support for using ßDG to identify patients at high risk of IC.
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Candida species are the most common fungal pathogens in the
intensive care unit (ICU) [1], and invasive candidiasis (IC) is
associated with considerable morbidity and mortality in criti-
cally ill patients [2, 3]. Early antifungal treatment reduces mor-
tality rates in patients with documented IC [4, 5], but a swift
deﬁnitive diagnosis is difﬁcult [6, 7]. Although prophylaxis or
preemptive treatment strategies should be used in patients at
high risk for IC [6, 8], their identiﬁcation is clinically challeng-
ing, because preemptive intervention markers have not been
fully deﬁned.
Risk factors for IC in critically ill patients include broad-
spectrum antibiotic exposure, cancer chemotherapy, fungal
colonization, indwelling vascular catheters, total parenteral
nutrition, surgery, renal failure, hemodialysis, and prolonged
ICU stay [9, 10]. Although these factors can be present
in patients who do not have IC and individually are not suf-
ﬁciently discriminatory, together they can still be used
to identify high-risk patients. Risk identiﬁcation strategies,
such as Candida colonization index [11], clinical predictive
rules [12, 13] and a Candida score [14, 15] have been
proposed to aid in deciding when to initiate early antifungal
therapy [7].
Antifungal prophylaxis in patients at high risk for IC has
been investigated in several randomized, controlled trials. Trials
in homogenous populations, such as surgical patients with re-
current gastrointestinal perforations or anastomotic leakages
[16] and severe acute pancreatitis [17], showed prophylaxis to
be an effective strategy, because infection rates were high with
placebo and signiﬁcantly lower with active antifungal therapy.
Studies with heterogeneous ICU patients, however had low in-
cidences of infections in the placebo arms, and treatment differ-
ences between placebo and active therapy were not shown [18–
24]. Therefore, antifungal prophylaxis should be used only in
speciﬁc subgroups where there is clear evidence of beneﬁt [7,
8, 25]. For the majority of ICU patients at high IC risk, a pre-
emptive antifungal strategy, based on clinical risk factors and
microbiologic evidence of substantial colonization, is proposed
[7, 8, 25].
Patients requiring ICU management after emergency surgery
for intra-abdominal infection have a high IC risk [26]. As
a commensal of the digestive tract, Candida may leak into the
peritoneal cavity after perforation or during surgical resection of
the intestine. Peritoneal seeding can result in intra-abdominal
Candida infection with risk of dissemination to the bloodstream
and extra-abdominal tissue and organs [27]. The INTENSE
(Invasive Candidiasis – Pre-emptive Treatment in High Risk
Surgical Subjects) study assessed the strategy of preemptive an-
tifungal therapy versus placebo in hospitalized patients requir-
ing surgery for intra-abdominal infection. Micafungin was used
as the active therapy, and the efﬁcacy and safety of its use in that
setting was assessed.
METHODS
Patients and Study Design
INTENSE (Clinicaltrials.gov identiﬁer NCT01122368) was an
exploratory, multicenter, randomized, double-blind, placebo-
controlled trial of preemptive antifungal therapy in adults
(aged ≥18 years), who presented with a generalized or localized
intra-abdominal infection requiring surgery and an ICU stay.
Patients were included if they had a community-acquired
(CAI) or nosocomially acquired (NAI) intra-abdominal
infection. Patients with CAI were those who presented with
intra-abdominal infection before or within 48 hours after
hospital admission. Patients with NAI were those who devel-
oped intra-abdominal infection >48 hours after hospital admis-
sion and were hospitalized for reasons other than infection. Key
exclusion criteria were acute pancreatitis, infected intra-perito-
neal dialysis, solid organ transplantation, severe liver disease, or
neutropenia at randomization. Exclusion criteria included re-
ceipt of a systemic antifungal within 14 days before study
drug, documented IC at randomization, or expected survival
<48 hours. The study was conducted from 13 July 2010 to 15
December 2011.
Eligible patients were randomized 1:1 to intravenous micafun-
gin (100 mg/d) or saline solution as a placebo. Patients were in-
cluded within 48 hours (NAI) or 72–120 hours (CAI) after
surgery providing they had an expected minimum ICU stay of
48 hours. Patientswere treated for 6weeks unless they experienced
an end of treatment (EOT) event: conﬁrmed IC, improvement in
surgical condition (as indicated by recovery of gastrointestinal
function allowing enteral feeding of up to 50% of daily calorie re-
quirement), alternative antifungal treatment, or death. If IC was
conﬁrmed, studymedicationwas discontinued and alternative an-
tifungal medication was given. The type of surgery and antibiotic
required for the treatment of the intra-abdominal infection were
prescribed according to center policy. The study was conducted
in accordance with the ethical principles originating in the Decla-
ration ofHelsinki.Written orwitnessed informed consentwas ob-
tained for all patients.
Outcome Measures and Assessments
Evaluation for IC
Patients were evaluated (Supplementary Appendix 1) for IC at
baseline, during treatment, at EOT assessment, and at the end of
study (EOS). The EOT assessment visit occurred within 1–3
days after the last dose of study medication, and the EOS visit
occurred 28 days after the last dose. Blinded assessments and
conﬁrmation of IC were made by an independent data review
board (IDRB) (P. E., C. L., and P. M.), as well as the investiga-
tors, based on histologic evidence at biopsy or positive culture
from blood, from a freshly placed peritoneal drain or biliary
catheter or intra-abdominal abscess.
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The coprimary efﬁcacy variables were the incidence of IDRB-
conﬁrmed IC diagnosed between baseline and EOT assessment
and the time from baseline to ﬁrst IDRB-conﬁrmed IC. The
start date of a conﬁrmed case was provided by the IDRB, and
the time to IC was calculated relative to the date of ﬁrst dose
of study drug. The incidence of IC according to the investigator
was also calculated. Post hoc analysis of the incidence of IC con-
ﬁrmed by the IDRB or an investigator (hereafter “any-
conﬁrmed” IC) was conducted for all patients and subgroups,
as described in Supplementary Appendix 2.
Biomarkers
The fungal biomarkers (1,3)-β-D-glucan (ßDG), Candida anti-
body, mannan antigen, and Candida were measured in blood
samples at baseline, during treatment and at the EOT assess-
ment; Candida antibody and mannan antigen were measured
with enzyme-linked immunosorbent assay, and Candida was
detected by polymerase chain reaction.
Safety
Treatment-emergent adverse events (AEs) and serious AEs, in-
cluding death, were recorded up to 90 days after EOT. Routine
laboratory assessments, including biochemistry, hematology,
and urinalysis, were performed at baseline and up to the EOS.
Statistical Methods
Power Calculation
A formal power calculation was not performed for this explor-
atory study, owing to a lack of suitable data on preventive ther-
apy studies at time of study design and therefore the use of
potentially poor estimates of parameters for sample size
calculations. It was considered that randomization of 125 pa-
tients per arm might allow observation of clinically important
differences in the incidence of IC, even with a 20% dropout rate.
Analysis Sets
Baseline characteristics, incidence and time to IDRB-conﬁrmed
IC, and biomarker data are reported for the full analysis set
(FAS), which comprised all randomized patients who received
≥1 dose of study medication and did not have an IDRB-
conﬁrmed IC at baseline. For the investigator-conﬁrmed IC, a
modiﬁed FAS was used, which took into account investigator-
conﬁrmed IC at baseline. Similarly for any-conﬁrmed IC
(conﬁrmed by the IDRB or investigator), a modiﬁed FAS was
used, which took into account the any-conﬁrmed IC at baseline.
The incidence and time to IDRB-conﬁrmed IC were further as-
sessed in the per-protocol set (PPS), deﬁned as all FAS patients
(1) who had an assessment of IC, as conﬁrmed by the IDRB at
EOT; (2) received ≥3 days of study medication; (3) had no con-
ﬁrmed IC before baseline, according to the IDRB; and (4) had no
major protocol violations. Prior and concomitant medication use
and safety assessments are described for the safety analysis set,
which included all randomized patients who received study med-
ication at least once.
Statistical Analysis
Unless otherwise stated, data are summarized using descriptive
statistics of mean (standard deviation [SD]) and median (where
not normally distributed) values for continuous variables, and
frequency and percentage for categorical data. The differences
in IC incidence between micafungin- and placebo-treated pa-
tients and the corresponding 95% conﬁdence intervals (CIs)
Figure 1. Patient ﬂow through the study. In the full analysis set (FAS), 30.7% of patients had either violated the protocol (10.4% had received concurrent
antifungal agents and 12.9% were outside the drug study window) or had received treatment for <3 days (11.6%). Abbreviations: IC, invasive candidiasis;
IDRB, independent data review board; PPS, per-protocol set.
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were derived using the Newcombe–Wilson method without
continuity correction. The time to IDRB-conﬁrmed IC was
modeled using the accelerated failure time model, a general
model for time-to-event data. The time to IDRB-conﬁrmed
IC was presented graphically by nonparametric Kaplan–Meier
curves, with patients without IDRB-conﬁrmed IC during the
treatment period censored either on the day of the EOT event
or at the EOT assessment. Statistical comparisons were per-
formed using log-rank tests.
Logistic regression was used to evaluate the impact of biomark-
ers on the binary response for IDRB-conﬁrmed IC. All 4 biomark-
ers were included in the model: ßDG (≥62.5 pg/mL for positive
response vs <62.5 pg/mL for negative), Candida polymerase
chain reaction (positive vs negative after >30 cycles), Candida
antibody (5.0–10.0 or >10.0 antibody units [AU]/mL for interme-
diate or positive, respectively, vs 5.0 AU/mL for negative), and
mannan antigen (62.5–125 or >125 pg/mL for intermediate or
positive vs <62.5 pg/mL for negative). Other covariates (continu-
ous and categorical) included in the model were age, sex, study
drug, CAI or NAI, and time from ICU admission to ﬁrst study
drug dose. Data analyses were performed using SAS software for
Windows (version 9.2 [2011]; SAS Institute).
RESULTS
Study Population
The study was conducted at 53 centers across 17 countries.
Participant ﬂow is shown in Figure 1. The FAS comprised
241 patients, 124 randomized to placebo and 117 to micafungin
(100 mg/d); baseline characteristics are provided in Table 1.
Study Drug Exposure
Themean (SD) duration of study drug exposure was 8.3 (6.9) days
for placebo and 7.7 (6.8) days for micafungin (median, 6 days for
both arms). In the placebo and micafungin arms, the percentages
of patients who received the study drug for <3 days (protocol de-
viations) were 9.7% and 13.7%, respectively; for 3–14 days, 79.0%
and 75.2%; and for >14 days, 11.2% and 11.1%.
Efﬁcacy
In the FAS, the IDRB-conﬁrmed IC incidence at EOT was 8.9%
(n = 11) for placebo and 11.1% (n = 13) for micafungin, for
an estimated difference of 2.24% (95%CI,−5.52 to 10.20) (Table 2).
The Candida species are listed in Table 3. Most infections occurred
in NAI patients; 9 of 11 in the placebo arm and 11 of 13 in the
micafungin arm. There was no difference between treatment
groups in the median time to IDRB-conﬁrmed IC; the time ratio
of micafungin relative to placebo was 0.69 (95% CI, .34–1.38). The
Kaplan–Meier failure curves are displayed in Figure 2. For patients
Table 1. Baseline Demographic and Clinical Characteristics (Full
Analysis Set)
Characteristic
Patients, No. (%)a
Placebo
(n = 124)
Micafungin
(n = 117)b
Total
(n = 241)
Sex
Male 41 (33.1) 50 (42.7) 91 (37.8)
Female 83 (66.9) 67 (57.3) 150 (62.2)
Age, mean (SD), y 63.0 (15.8) 61.6 (14.8) 62.3 (15.3)
Age group
18–65 y 63 (50.8) 66 (56.4) 129 (53.5)
>65 y 61 (49.2) 51 (43.6) 112 (46.5)
Type of intra-abdominal infection
CAI 45 (36.3) 41 (35.0) 86 (35.7)
NAI 79 (63.7) 76 (65.0) 155 (64.3)
Abbreviations: CAI, community-acquired infection; NAI, nosocomially acquired
infection; SD, standard deviation.
a Data represent No. (%) except where otherwise indicated.
b Micafungin 100 mg/d.
Table 2. Incidence of Invasive Candidiasis in the Full Analysis Set and Per-Protocol Set for All Patients
IC Incidence
Patient With IC/Total Patients, No. (%)
Placebo Micafunginb
Treatment Difference
(Micafungin− Placebo), % (95% CI)
All patients (FAS)
IDRB-confirmed IC 11/124 (8.9) 13/117 (11.1) 2.24 (−5.52 to 10.20)
Investigator-confirmed ICa 20/121 (16.5) 16/116 (13.8) −2.74 (−11.92 to 6.56)
Any-confirmed ICa 20/120 (16.7) 17/115 (14.8) −1.88 (−11.24 to 7.58)
All patients (PPS)
IDRB-confirmed IC 5/88 (5.7) 5/79 (6.3) 0.65 (−7.17 to 8.95)
Abbreviations: CI, confidence interval; FAS, full analysis set; IC, invasive candidiasis; IDRB, independent data review board; PPS, per-protocol set.
a FAS was modified according to who assessed for IC at baseline. Any-confirmed IC includes IC confirmed by IDRB and/or investigator.
b Micafungin 100 mg/d.
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without an IDRB-conﬁrmed IC, the most common EOT event
was sufﬁcient improvement in surgical condition (Table 4). The
results obtained in the PPS for incidence (Table 2) and time to
IDRB-conﬁrmed IC (time ratio of micafungin relative to placebo,
0.80, 95% CI, .26–2.50) were consistent with those in the FAS.
In the FAS, the investigators diagnosed IC in 20 patients
(16.5%) in the placebo arm and 16 (13.8%) in the micafungin
arm (Table 2). The incidence of any-conﬁrmed IC was also
lower for micafungin than for placebo for all patients (Table 2),
as well as for all post hoc subgroups considered to have a higher
risk of IC, although the CIs included 0 (Figure 3).
Biomarkers
Biomarker results are reported for ßDG data, which were
available for 41% of the FAS population. The mean (SD)
change from baseline at the EOT assessment for ßDG was
+53 (356) pg/mL in the placebo arm (n = 54) and −35 (207)
pg/mL in the micafungin arm (n = 44). Logistic regression
modeling used to evaluate the impact of biomarkers on the bi-
nary response for IDRB-conﬁrmed IC showed only ßDG to be
related to the response, with an odds ratio of 3.66 (95% CI,
1.01–13.29).
Safety
AEs and deaths are reported in Supplementary Appendix 3.
There were no clinically signiﬁcant differences between study
arms in the mean biochemical, hematologic, and urinalysis pa-
rameters analyzed between baseline and either EOT or EOS. Al-
anine aminotransferase levels were similar between treatment
groups (Supplementary Appendix 3; Figure 1).
Table 3. Type and Frequency of Candida Species Conﬁrmed by
Independent Data Review Board at the End of Treatment
Candida Species
Cultures Positive for Candida Species, No.a
Placebo Micafungin
Blood
Culture
Other
Cultureb
Blood
Culture
Other
Cultureb
C. albicans 1 6 2 7
C. glabrata 1 3 1 0
C. parapsilosis 1 1 0 1
C. tropicalis 0 2 0 0
C. dubliniensis 0 2 0 0
Not identified to
species level
2 2 2 3
a Some patients were infected with >1 Candida species.
b Other culture sites included freshly placed peritoneal drain or biliary catheter
and intra-abdominal abscess.
Figure 2. Kaplan–Meier failure curves of time to independent data review board (IDRB)-conﬁrmed invasive candidiasis (IC) (full analysis set).
Table 4. End of Treatment Events (Full Analysis Set)
Reason for EOT
EOT Events, No. (%)
Placebo
(n = 124)
Micafungin
(n = 117)b
IDRB-confirmed IC 11 (8.9) 13 (11.1)
No IDRB-confirmed IC, 113 (91.1) 104 (88.9)
Sufficient improvement 78 (62.9) 75 (64.1)
Alternative antifungal therapy 8 (6.5) 5 (4.3)
Death 1 (0.8) 5 (4.3)
Other reasons for EOTa 25 (20.2) 18 (15.4)
Maximum 6-wk treatment 1 (0.8) 1 (0.9)
Abbreviations: EOT, end of treatment; IC, invasive candidiasis; IDRB,
independent data review board.
a Other reasons include investigator-confirmed IC, adverse events, lack of
efficacy, and protocol violation.
b Micafungin 100 mg/d.
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DISCUSSION
The INTENSE study did not provide evidence to support the
use of a preemptive antifungal strategy in high-risk surgical pa-
tients with intra-abdominal infections. In the FAS, the patient
selection criteria successfully identiﬁed an IDRB-conﬁrmed in-
cidence rate of 8.9% in the placebo arm. However, the incidence
of 11.1% in the micafungin arm was unexpected. Because mica-
fungin is an effective treatment for candidemia and IC, this sug-
gests that IC might have been established in these patients and
preemptive therapy was administered too late. This supposition
is supported by the relatively high number of baseline IC cases
(Figure 1), with the majority of emergent IC cases within the
ﬁrst few study days (Figure 2).
A similar lack of evidence for a prophylaxis antifungal strat-
egy in at-risk ICU patients was found in a randomized, placebo-
controlled study of caspofungin [24]. A lower-than-expected IC
incidence resulted in a lack of difference between placebo
(16.7%) and caspofungin (9.8%). A comparison between pre-
emptive and empiric antifungal therapy with anidulafungin
also showed no difference between strategies in the incidence of
IC in ICU patients [28]. Antifungal treatment administered in
the absence of a proven IC diagnosis was found to have no effect
on mortality rates or IC occurrence compared with no treat-
ment in critically ill patients receiving mechanical ventilation,
possibly owing to the absence of actual IC [29]. These studies,
together with ours, highlight the challenge of demonstrating the
beneﬁt of antifungals in the absence of proven IC, even in ICU
patient populations with multiple risk factors for IC.
The challenge of early IC identiﬁcation in the surgical setting
is widely recognized [26], and for this reason we used blinded
assessment and conﬁrmation of IC by an independent panel
of experts. The incidence was higher with investigator-
diagnosed IC (16.5% for placebo in the FAS), and only some
diagnosed infections overlapped with those assessed by the
IDRB. The disparity between the IDRB and investigators in
the incidence of conﬁrmed IC, a phenomenon observed in
other studies [30, 31], again illustrates the difﬁculty in early
identiﬁcation of IC.
Preliminary studies investigating ßDG in ICU patients found
higher ßDG levels in those with IC than in those without IC [24,
28, 32], and its detection has been shown to precede a microbi-
ologic diagnosis by several days [33, 34]. In our study, ßDG was
the only biomarker correlating with conﬁrmed IC, although
ßDG measurements were not available for all patients.
Micafungin was well tolerated in these patients, with one-half
the incidence of pyrexia, wound infection, vomiting, and pleural
effusion compared with placebo. The incidence of anemia was
slightly higher in micafungin-treated patients than in those re-
ceiving placebo. No hepatobiliary AEs were related to micafun-
gin. There was no clinically relevant difference in mortality rates
between micafungin and placebo.
Statistical powering of prophylaxis and preemptive trials in
ICU patients is difﬁcult, and for this reason INTENSE was
designed to be an exploratory study and was not formally
powered. We recognize this as a limitation of our study. Any
P values are considered nominal and only hypothesis generating
rather than conclusive. Other limitations include the possible
Figure 3. Incidence of conﬁrmed cases of invasive candidiasis (IC) by higher-risk subgroups (full analysis set, modiﬁed according to who assessed for IC at
baseline; cases were conﬁrmed by independent data review board and/or investigator). Abbreviations: CI, conﬁdence interval; NAI, nosocomially acquired
infection.
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inclusion of patients who already had established IC and difﬁ-
culty on the part of the investigators in deciding which patients
should be enrolled in this study, as highlighted by the fact that
31% of patients in the FAS were excluded from the PPS.
Several key ﬁndings from the INTENSE study should be con-
sidered in future studies of preventive antifungal strategies in
critically ill patients. The type of treatment strategy needs to
be classiﬁed by current deﬁnitions as prophylactic, preemptive,
or empiric [7], because this classiﬁcation determines the timing
of treatment. These deﬁnitions have evolved from when the IN-
TENSE study was designed, and with hindsight it could be con-
sidered a prophylaxis study. Identiﬁcation of ICU patients at
high risk for IC is challenging and requires careful selection
of patients. In our study for example, the overall incidence of
IC (any-conﬁrmed cases) in the NAI subgroup was 21%, con-
ﬁrming that this might be a population worth focusing on in
future studies, whereas the infection rate in the CAI group
was very low. We echo a point made by Montravers et al [27],
that additional tools and prediction rules to identify patient
populations with the highest risk are required. Our data add
to the evidence that, in conjunction with risk factors, ßDG
has potential use as a marker to help physicians select high-
risk patients who might beneﬁt from early antifungal treatment.
Our ﬁndings support the need for further investigations on
these measures as criteria in prediction rules.
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